Zacks: Brokerages Anticipate Myomo, Inc. (NASDAQ:MYO) to Announce -$1.75 EPS

Equities analysts expect Myomo, Inc. (NASDAQ:MYO) to announce earnings of ($1.75) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Myomo’s earnings. The highest EPS estimate is ($1.54) and the lowest is ($1.95). Myomo reported earnings of ($5.11) per share in the same quarter last year, which suggests a positive year over year growth rate of 65.8%. The company is expected to issue its next earnings report on Monday, May 11th.

On average, analysts expect that Myomo will report full year earnings of ($4.30) per share for the current fiscal year, with EPS estimates ranging from ($5.20) to ($3.40). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.27) per share, with EPS estimates ranging from ($3.28) to ($1.25). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Myomo.

MYO stock traded up $0.07 during midday trading on Thursday, hitting $3.79. The company’s stock had a trading volume of 1,213 shares, compared to its average volume of 703,434. Myomo has a 52-week low of $2.82 and a 52-week high of $40.00. The firm has a 50-day simple moving average of $6.57 and a 200-day simple moving average of $2.21.

About Myomo

Myomo, Inc, a commercial stage medical robotics company, designs, develops, and produces myoelectric braces or orthotics for people suffering with neuromuscular disorders in the United States. It offers MyoPro, a powered upper limb orthosis that supports the arm, as well as restores function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, ALS, or other neuromuscular disease or injury.

Featured Story: What is a Market Correction?

Get a free copy of the Zacks research report on Myomo (MYO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with's FREE daily email newsletter.